成人免费看AA片,18以下勿进色禁网站永久,2020亚洲А∨天堂在线直播

EN| News Releases
News Releases

News Releases

Home>News Releases
China Resources Pharmaceutical Ranks No.2 of Top 10 China Enterprises in the PRC Pharmaceutical Industry Again

Press time:2016-11-18From:CR Pharma [Font:BigMediumSmall]

The “China ChemPharm Annual Summit 2016” which jointly organized by China Pharmaceutical Industry Association, China Association of Pharmaceutical Commerce, China Nonprescription Medicines Association and China Pharmaceutical Enterprises Development Promote Association was held in Wuhan, China on November 15th,2016. The “Excellent enterprises and brands in the PRC Chemical Pharmaceutical Industry of 2016” was released during the summit. China Resources Pharmaceutical (“CR Pharma”) ranks 2nd on “Top 10 China Enterprises in the PRC Chemical Pharmaceutical Industry of 2016” listing.

CR Pharma’s subsidiaries, including CR Double-Crane, CR Zizhu and CR Saike were all listed on the “Top 100 Enterprises in the PRC Chemical Pharmaceutical Industry of 2016”, which ranks 21st, 73rd and 79th respectively. “Compound Dexamethasone Acetate Cream (Pi Yan Ping)” from CR Sanjiu continually won the “Excellent OTC brand in PRC Chemical Pharmaceutical Industry” award. At the same time, “Pitavastatin Calcium Tablets (Guan Shuang)”, “Levofloxacin” ,“Sodium Chloride Injection (Ying Yuan)”, “ Gliquidone” and basic injection products from CR Double-Crane, “Amlodipine Besylate Tablets (Ya Shi Da)” and “Valsartan Capsules (Hui Yue)” from CR Saike, “Levonorgestrel  Tablets (Yu Ting)” and “Jin Yuting” from CR Zizhu won the awards of “Excellent Brand”.

The theme of the summit this year was “Quality, Integrity and Brand”. The summit was a great opportunities for deep communication between Chemical Pharmaceutical enterprises in terms of understanding national relevant policies, analyzing pharmaceutical economic trend and publishing construction of drug traceability system, credit evaluation of pharmaceutical enterprises and etc.

CR Pharma will continue to pursue strategic acquisitions and to focus on research and innovation to further upgrade core competitiveness, to consolidate the leadership positions in the pharmaceutical industry and to provide high quality products and high value services to customers.

Back to Top

  • <menuitem id="bgbmp"><rp id="bgbmp"><em id="bgbmp"></em></rp></menuitem>

    <form id="bgbmp"></form>
  • <strong id="bgbmp"><strong id="bgbmp"><object id="bgbmp"></object></strong></strong>

    主站蜘蛛池模板: 庆阳市| 诏安县| 余江县| 娱乐| 噶尔县| 建德市| 莒南县| 宁河县| 页游| 临漳县| 保定市| 镇宁| 西城区| 肃宁县| 从江县| 沿河| 柞水县| 东兴市| 龙泉市| 禄丰县| 临沭县| 共和县| 安溪县| 攀枝花市| 康平县| 临颍县| 称多县| 白银市| 五大连池市| 鸡东县| 颍上县| 茂名市| 新余市| 丹东市| 洛隆县| 高台县| 木兰县| 咸宁市| 乌兰县| 沁水县| 阿拉善左旗|